Bristol-Myers price target lowered to $65 from $66 at Barclays

Barclays lowered the firm’s price target on Bristol-Myers to $65 from $66 and keeps an Equal Weight rating on the shares. The analyst says the company’s Q1 update reinforces rather than addresses key questions.